Pair page
Mazdutide with Pemvidutide
Mechanism-tag overlap and published literature for Mazdutide and Pemvidutide, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
Mazdutide unique
incretin-peptide
Shared
dual-glp-1-glucagon-receptor-agonist
Pemvidutide unique
none
Quick facts
Mazdutide
RouteSubQ once weekly
Half-lifeWeekly dosing compatible
FDA statusNot approved
WADANot listed
Pemvidutide
RouteWeekly SubQ
Half-life~4 days (weekly SubQ)
FDA statusPhase 2 (obesity, MASH)
WADANot listed
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Mazdutide | Ji L, Jiang H, Bi Y, Li H, Tian J, Liu D, et al; GLORY-1 Investigators. Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025;392(22):2215-2225. PMID: 40421736. DOI: 10.1056/NEJMoa2411528. (Pivotal GLORY-1 Phase 3 publication, May 2025.) PMID 40421736 | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, Qian L, et al; DREAMS-1 Investigators. Mazdutide in Chinese adults with untreated type 2 diabetes: DREAMS-1 Phase 3 trial. Nature. 2025. (Accelerated Article Preview publication, late 2025; part of back-to-back Nature release.) | human trial, Phase 3 |
| 2025 | Mazdutide | Ji L, et al; DREAMS-2 Investigators. Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes inadequately controlled on oral medication: DREAMS-2 Phase 3 trial. Nature. 2025. (Back-to-back with DREAMS-1.) | human trial, Phase 3 |
| 2025 | Mazdutide | Innovent Biologics press release. Nature | Two Phase 3 Clinical Results of Mazdutide (GLP-1/GCG Dual Receptor Agonist) in Chinese Adults with Type 2 Diabetes Have Been Back-to-Back Published in Nature. November 2025. | human trial, Phase 3 |
| 2025 | Mazdutide | BioSpace press release. Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3). May 15, 2025. | human trial, Phase 3 |
| 2018 | Mazdutide | Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, et al. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study. Lancet. 2018;391(10… PMID 29945726 | human trial, Phase 2 |
| 2022 | Mazdutide | Ji L, Gao L, Jiang H, Yang J, Yu L, Wen J, et al. Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial. EClinical… PMID 36337827 | human trial, Phase 1 |
| 2022 | Mazdutide | Jiang H, Pang S, Zhang Y, Yu T, Liu M, Deng H, et al. A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes. Nat Commun. 2022;13(1):3613. PMID: 35750890. (Phase 1b / dose… PMID 35750890 | human trial, Phase 1 |
| 2025 | Mazdutide | Innovent Biologics press release. Innovent Announces Mazdutide Received Approval from China's NMPA for Glycemic Control in Adults with Type 2 Diabetes. September 19, 2025. | human study |
| 2017 | Mazdutide | Sánchez-Garrido MA, Brandt SJ, Clemmensen C, Müller TD, DiMarchi RD, Tschöp MH. GLP-1/glucagon receptor co-agonism for treatment of obesity. Diabetologia. 2017;60(10):1851-1861. PMID: 28733905. (Class review.) PMID 28733905 | human study |
| 2009 | Mazdutide | Pocai A, Carrington PE, Adams JR, Wright M, Eiermann G, Zhu L, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes. 2009;58(10):2258-2266. PMID: 19602537. (Preclinical proof-of-concept for the dual-agonist class.) PMID 19602537 | preclinical, in vivo |
| 2018 | Mazdutide | Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641. (GLP-1 mechanism framework.) PMID 29617641 | research article |
| 2024 | Pemvidutide | Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PMID: 38324484. (First FDA-approved MASH dr… PMID 38324484 | human trial, Phase 3 |
| 2024 | Pemvidutide | le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. Lancet Diabetes Endocrinol. 2024;12(3):162-173. PMID: 38335975. (Survod… PMID 38335975 | human trial, Phase 2 |
| 2024 | Pemvidutide | Altimmune Inc. Q1–Q4 2024 and Q1 2025 earnings calls and investor presentations. Altimmune.com / SEC filings. (Phase 2 MOMENTUM and IMPACT interim and topline disclosures.) | human trial, Phase 2 |
| 2023 | Pemvidutide | Altimmune Inc. Pemvidutide (ALT-801) — Corporate Pipeline and Clinical Development Program Disclosures. 2023–2025. (Phase 2 MOMENTUM and IMPACT trial sponsor disclosures.) | human trial, Phase 2 |
| 2023 | Pemvidutide | Jastreboff AM, Kaplan LM, Frías JP, Wu Q, Du Y, Gurbuz S, Coskun T, Haupt A, Milicevic Z, Hartman ML. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315. (Retatrutide competitor — triple agonist.) PMID 37366315 | human trial, Phase 2 |
| 2018 | Pemvidutide | Ambery P, Parker VE, Stumvoll M, Posch MG, Heise T, Plum-Moerschel L, Tsai LF, Robertson D, Jain M, Petrone M, Rondinone C, Hirshberg B, Jermutus L. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controll… PMID 29945727 | human trial, Phase 2 |
| 2018 | Pemvidutide | Ambery P, et al. MEDI0382, a GLP-1/glucagon dual agonist, in type 2 diabetes: phase 2 efficacy and safety. Diabetologia. 2018;61(3):564-573. (Early GLP-1/GCGR class data.) | human trial, Phase 2 |
| 2022 | Pemvidutide | Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. (Tirzepatide SURMOUNT-1 foundational obesity trial for cl… PMID 35658024 | human trial |
| 2021 | Pemvidutide | Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-100… PMID 33567185 | human trial |
| — | Pemvidutide | ClinicalTrials.gov. A Study to Evaluate the Efficacy and Safety of Pemvidutide (ALT-801) in Adults Who Are Overweight or Obese (MOMENTUM). NCT05295875. | human trial |
| 2021 | Pemvidutide | Nahra R, Wang T, Gadde KM, Oscarsson J, Stumvoll M, Jermutus L, Hirshberg B, Ambery P. Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes. Diabetes Care. 2021;44(6):1433-1442. PMID: 33893157. (Cotadutide hepatic eff… PMID 33893157 | human study |
| 2021 | Pemvidutide | Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754-762. PMID: 33269530. (GLP-1 class appetit… PMID 33269530 | human study |
Related pair pages
More research context
Frequently asked
Have Mazdutide and Pemvidutide been studied together?
No co-administration studies between Mazdutide and Pemvidutide are catalogued on Kalios. The pair page lists only the individual published literature for each compound and any shared mechanism tags.
What mechanisms do Mazdutide and Pemvidutide share?
Mazdutide and Pemvidutide share these mechanism tags on their Kalios profiles: dual-glp-1-glucagon-receptor-agonist. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Mazdutide and Pemvidutide?
Mazdutide: Not approved. Pemvidutide: Phase 2 (obesity, MASH). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Mazdutide and Pemvidutide?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Mazdutide profile and the Pemvidutide profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026